Dicamba is a toxic, volatile herbicide linked to widespread crop destruction and serious health risks. Across the United States, farmers and agricultural workers report devastating losses after dicamba drifted far beyond where it was applied. Even more alarming, emerging scientific research links dicamba exposure to liver and bile duct cancer.
Salenger, Sack, Kimmel & Bavaro, LLP is actively representing individuals and farmers nationwide in dicamba herbicide lawsuits against Monsanto and other manufacturers. If your crops were damaged—or if you or a loved one developed bile duct cancer after dicamba exposure—you may be entitled to financial compensation.
📞 Call 800-675-8556 for a free, confidential consultation.
Dicamba is a selective herbicide used to kill broadleaf weeds. It is found in more than 1,100 agricultural products sold throughout the U.S. Dicamba works by mimicking natural plant hormones (auxins), causing uncontrolled growth that ultimately kills weeds.
Since 2017, dicamba has been approved for over-the-top (OTT) use on genetically engineered soybeans and cotton designed to tolerate it. However, this approval triggered unprecedented off-target damage, as dicamba does not stay where it is sprayed.
According to the U.S. Environmental Protection Agency, more than one million acres of non-dicamba-tolerant soybeans were allegedly damaged in a single growing season.
One of the most dangerous aspects of dicamba is its volatility. In heat and humidity, dicamba can evaporate after application and form a vapor cloud that travels miles away—damaging crops that were never sprayed.
Farmers across the Midwest and South have reported dicamba damage to:
Many affected farmers never used dicamba at all. Instead, the herbicide drifted from neighboring fields—or even from farms across state lines.
Farmers involved in dicamba lawsuits frequently report:
Even minimal exposure can cause irreversible economic damage.
Dicamba’s harm is not limited to crops.
A recent scientific study found that dicamba exposure is associated with an increased risk of liver and intrahepatic bile duct cancers. These cancers—collectively known as cholangiocarcinoma—are rare but highly aggressive, with poor long-term survival rates.
Individuals at risk include:
If you developed liver bile duct cancer after long-term dicamba exposure, you may qualify for a dicamba cancer lawsuit.
Bile duct cancer begins in the ducts that carry bile from the liver and gallbladder to the small intestine. Subtypes include:
Survival rates are low, particularly when diagnosed at advanced stages. Many cases are discovered late due to vague early symptoms.
If you or a loved one has been diagnosed with cancer and believe it was from Dicamba usage, don’t wait to seek legal help.
Contact Salenger, Sack, Kimmel & Bavaro today for a FREE consultation.
Call (800) 675-8556 or contact us online to get started.
Dicamba lawsuits allege that manufacturers—including Monsanto and BASF—knew their dicamba formulations were volatile, prone to drift, and unsafe for their intended use.
Claims allege that these companies:
Products named in litigation include XtendiMax, Engenia, and FeXapan.
In February 2018, the Judicial Panel on Multidistrict Litigation centralized dicamba lawsuits in a federal MDL in the Eastern District of Missouri.
These outcomes confirm what farmers have known for years: dicamba causes widespread, foreseeable damage.
After record-breaking crop damage reports, the EPA repeatedly amended dicamba regulations and imposed additional restrictions in multiple states, including Iowa, Illinois, Indiana, Minnesota, and South Dakota.
Despite these efforts, dicamba damage has continued—highlighting the inherent dangers of the product, even when used “as directed.”
You may be eligible if:
Our dicamba attorneys can evaluate your claim at no cost.
Dicamba has devastated farms, livelihoods, and lives. Whether you are facing massive crop losses or a life-altering cancer diagnosis, you deserve accountability.
📞 Call us at 800-675-8556
📩 Or complete our secure online form for a FREE consultation.